MACROD2 and colonic neoplasm: In stage III colon cancers, however, low expression of MACROD2 showed a poorer DFS than high expression of MACROD2, although this difference did not reach statistical significance (p=0.07; HR=1.6, 95% CI 1.0-2.7; Figure 2D).